Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma

NCT02596971 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02596971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02596971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Completed
Start date
December 22, 2015
Completion date
May 8, 2020
Enrollment
91 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, lymphoma follicular